Mystic Asset Management Inc. Cuts Stock Position in Pfizer Inc. $PFE

23 Apr 2026, 08:30 by Amy Steele · The Cerbat Gem

Mystic Asset Management Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 18.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 179,676 shares of the biopharmaceutical company’s stock after selling 39,546 shares during the period. Pfizer makes up about 1.0% of Mystic Asset Management Inc.’s investment portfolio, making the stock its 24th biggest position. Mystic Asset Management Inc.’s holdings in Pfizer were worth $4,474,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Northern Trust Corp increased its position in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Legal & General Group Plc increased its position in shares of Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares during the last quarter. Finally, Amundi increased its position in shares of Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after purchasing an additional 4,043,413 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $26.78 on Thursday. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market cap of $152.28 billion, a price-to-earnings ratio of 19.69 and a beta of 0.43. The company has a 50-day moving average price of $27.26 and a two-hundred day moving average price of $26.05.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s dividend payout ratio is 126.47%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Guggenheim boosted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, UBS Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.48.

Get Our Latest Report on Pfizer

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; record/ex‑div May 8), the 350th consecutive quarterly payout — supports income investors and signals cash‑flow confidence. Pfizer Declares Second-Quarter 2026 Dividend
Positive Sentiment: Pfizer’s GLP‑1 weight‑management drug Xianweiying is available for pre‑order in China — early commercialization there could materially expand revenue opportunity versus peers. Pfizer GLP-1 weight loss drug available for pre-order in China
Positive Sentiment: Company to present broad oncology pipeline data at ASCO (multiple abstracts, late‑breaking sessions) — positive for long‑term growth if trial readouts show benefit. Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
Neutral Sentiment: Analysts maintain mixed views — the consensus rating is “Hold,” reflecting cautious expectations despite recent execution. Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
Neutral Sentiment: Preview pieces note Pfizer’s history of modest earnings beats and margin improvement from cost cuts — upcoming results could surprise but uncertainties (patent cliffs, product mix) remain. Pfizer Could Surprise Again This Earnings Season (Preview)
Negative Sentiment: Barclays reiterated a “Sell” — a high‑profile sell rating increases downward pressure on sentiment and trading. Barclays Remains a Sell on Pfizer (PFE)
Negative Sentiment: Royal Bank of Canada assigned an Underperform — another downgrade that can pressure the share price and reduce buy‑side conviction. Pfizer (NYSE:PFE) Earns Underperform Rating from Royal Bank Of Canada
Negative Sentiment: Top strategy executive is leaving — leadership turnover creates short‑term execution risk and may add to investor caution. Pfizer’s top strategy executive is leaving

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.